Loading...
XSHE
300194
Market cap698mUSD
Oct 09, Last price  
4.03CNY
1D
2.54%
1Q
11.63%
Jan 2017
-54.03%
IPO
-41.40%
Name

Fuan Pharmaceutical Group Co Ltd

Chart & performance

D1W1MN
XSHE:300194 chart
P/E
62.27
P/S
2.78
EPS
0.06
Div yield, %
1.78%
Shrs. gr., 5y
0.03%
Rev. gr., 5y
-6.78%
Revenues
1.73b
-27.78%
198,457,058324,528,285464,010,492358,548,287420,017,314357,779,550448,569,651708,096,0411,297,016,9102,090,806,8492,669,296,0812,780,740,6462,368,343,2962,453,144,9202,453,144,9202,421,742,2922,421,742,2912,647,752,9532,391,468,1051,727,110,055
Net income
77m
-72.49%
45,698,95390,670,604123,136,91595,233,59688,505,12038,367,91745,707,27864,899,365221,958,233284,814,669-359,976,330292,829,534209,369,5330-296,913,077204,607,567204,607,570231,869,166279,837,28276,997,129
CFO
336m
+10.75%
18,916,52349,226,87362,747,733105,743,38064,851,07662,766,74189,610,1660161,026,698374,162,616453,370,240267,675,482295,627,587162,552,887257,128,839339,498,850328,978,126303,586,355336,231,321
Dividend
May 28, 20260.05 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Fuan Pharmaceutical (Group) Co., Ltd. is a comprehensive pharmaceutical enterprise that, along with its subsidiaries, undertakes the research, development, manufacturing, and commercialization of pharmaceutical products across the People's Republic of China. Its product portfolio spans intermediate compounds, active pharmaceutical ingredients (APIs), and finished drug formulations. These formulations cater to a range of therapeutic categories, including anti-infective agents, cardiovascular medications, digestive system remedies, and various other medical products. The group was founded in 2004 and is headquartered in Chongqing, China. It adopted its current name, Fuan Pharmaceutical (Group) Co., Ltd., in August 2013, having previously been known as Chongqing Fuan Pharmaceutical (Group) Co., Ltd.

Key people

Xuesong yu
Chief Financial Officer, Finance Director, Deputy General Manager, Director · since 2024
Lu Wang
General Manager, Director · since 2024
Jing Feng
Deputy General Manager
Wei Wang
Deputy General Manager · since 2024
Qin Tang
Secretary of the Board, Director · since 2009
Tao Huang
Vice Chairman of the Board, Deputy General Manager · since 2024
Tianxiang Wang
Chairman of the Board · since 2023
Yong Yang
Director · since 2024
Geng Chen
Independent Director
Zhi Dong
Independent Director · since 2024
Zhiqiang Liu
Independent Director · since 2024
URL
https://www.fapharm.com/
IPO date
Mar 22, 2011
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122023‑002022‑122022‑002021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT